联亚药业(301569)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

301569 联亚药业

已收盘 11-04 15:00:00

{"stockData":{"symbol":"301569","market":"SZ","secType":"STK","nameCN":"联亚药业","latestPrice":21.11,"timestamp":1793775780000,"preClose":19.6,"halted":0,"volume":58244889,"delay":0,"changeRate":0.077,"floatShares":117000000,"shares":892000000,"eps":0.3491,"marketStatus":"已收盘","change":1.51,"latestTime":"11-04 15:00:00","open":19.62,"high":23.51,"low":19.62,"amount":1249000000,"amplitude":0.1985,"askPrice":21.12,"askSize":91,"bidPrice":21.11,"bidSize":1450,"shortable":0,"etf":0,"ttmEps":0.3491,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793842200000},"marketStatusCode":5,"adr":0,"adjPreClose":19.6,"symbolType":"stock","openAndCloseTimeList":[[1793755800000,1793763000000],[1793768400000,1793775600000]],"highLimit":21.56,"lowLimit":17.64,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":891597091,"isCdr":false,"pbRate":7.66,"roa":"--","peRate":60.469779,"roe":"10.55%","epsLYR":0.3,"committee":0.871672,"marketValue":18822000000,"turnoverRate":0.4985,"status":0,"floatMarketCap":2467000000},"requestUrl":"/m/hq/s/301569","defaultTab":"news","newsList":[{"id":"2680775466","title":"股市必读：联亚药业（301569）登11月3日交易所龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2680775466","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680775466?lang=zh_cn&edition=full","pubTime":"2026-11-04 01:09","pubTimestamp":1793725771,"startTime":"0","endTime":"0","summary":"截至2026年11月3日收盘，联亚药业报收于19.6元，上涨1.66%，换手率35.2%，成交量41.12万手，成交额7.8亿元。当日关注点交易信息汇总：11月3日主力资金净流入2538.39万元，占总成交额3.26%；  交易信息汇总：联亚药业因日换手率达30%登上龙虎榜，系近5个交易日内第3次上榜。坚定持有联亚药业~向你们致敬。！公司目前暂未在AI制药方向进行布局。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110400002279.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301569","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680291187","title":"联亚药业：公司目前暂未在AI制药方向进行布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2680291187","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680291187?lang=zh_cn&edition=full","pubTime":"2026-11-03 20:48","pubTimestamp":1793710136,"startTime":"0","endTime":"0","summary":"证券之星消息，联亚药业(301569)11月03日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵司在Ai制药方向有无布局？联亚药业回复：尊敬的投资者您好！公司目前暂未在AI制药方向进行布局。公司将持续关注AI技术在医药研发领域的行业发展与应用前景，如后续有相关规划，公司将严格按照相关规定及时履行披露义务。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110300040450.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1191","BK1574","01477","301569"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680756641","title":"11月2日联亚药业（301569）龙虎榜数据：机构净卖出1847.32万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2680756641","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680756641?lang=zh_cn&edition=full","pubTime":"2026-11-02 19:18","pubTimestamp":1793618332,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年11月2日公布的交易公开信息显示，联亚药业因日换手率达到30%的前5只证券登上龙虎榜。此次是近5个交易日内第2次上榜。截至2026年11月2日收盘，联亚药业报收于19.28元，上涨5.82%，换手率33.75%，成交量39.43万手，成交额7.33亿元。从龙虎榜公布的当日买卖数据来看，机构合计净卖出1847.32万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200028819.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301569","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680786997","title":"联亚药业（301569）10月30日主力资金净买入2560.00万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2680786997","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680786997?lang=zh_cn&edition=full","pubTime":"2026-11-02 09:06","pubTimestamp":1793581614,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月30日收盘，联亚药业报收于18.22元，上涨2.47%，换手率37.13%，成交量43.39万手，成交额8.14亿元。近5日资金流向一览见下表：联亚药业融资融券信息显示，融资方面，当日融资买入4372.45万元，融资偿还6306.7万元，融资净偿还1934.25万元。联亚药业主营业务：复杂药物制剂的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110200003288.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301569","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679825131","title":"联亚药业（301569）10月29日主力资金净卖出7489.78万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2679825131","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679825131?lang=zh_cn&edition=full","pubTime":"2026-10-30 09:23","pubTimestamp":1793323414,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月29日收盘，联亚药业报收于17.78元，下跌6.32%，换手率28.5%，成交量33.3万手，成交额6.07亿元。近5日资金流向一览见下表：联亚药业融资融券信息显示，融资方面，当日融资买入3799.41万元，融资偿还4299.16万元，融资净偿还499.76万元。联亚药业主营业务：复杂药物制剂的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000017086.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301569"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679472557","title":"联亚药业(301569.SZ)发布前三季度业绩，归母净利润2.26亿元，同比增长58.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679472557","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679472557?lang=zh_cn&edition=full","pubTime":"2026-10-29 18:21","pubTimestamp":1793269282,"startTime":"0","endTime":"0","summary":"智通财经APP讯，联亚药业(301569.SZ)发布2026年三季度报告，前三季度，公司实现营业收入7.47亿元，同比增长18.07%。归属于上市公司股东的净利润2.26亿元，同比增长58.32%。归属于上市公司股东的扣除非经常性损益的净利润2.24亿元，同比增长61.04%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1515268.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["301569"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679490024","title":"联亚药业（301569）10月28日主力资金净卖出340.27万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2679490024","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679490024?lang=zh_cn&edition=full","pubTime":"2026-10-29 09:12","pubTimestamp":1793236362,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月28日收盘，联亚药业报收于18.98元，上涨5.8%，换手率33.35%，成交量38.97万手，成交额7.17亿元。近5日资金流向一览见下表：联亚药业融资融券信息显示，融资方面，当日融资买入4079.57万元，融资偿还4325.34万元，融资净偿还245.76万元。联亚药业主营业务：复杂药物制剂的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102900015979.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301569"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678125439","title":"联亚药业：除美国外，公司已有产品在加拿大获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2678125439","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678125439?lang=zh_cn&edition=full","pubTime":"2026-10-28 11:33","pubTimestamp":1793158394,"startTime":"0","endTime":"0","summary":"证券之星消息，联亚药业(301569)10月28日在投资者关系平台上答复投资者关心的问题。投资者提问：你好！除了美国那边销售，目前其他国家是否有计划或者说是已经在准备阶段？你们家3年内销售额有没有计划突破50亿？联亚药业回复：尊敬的投资者您好！除美国外，公司已有产品在加拿大获批，同时公司正加大国内市场开拓，业绩情况请关注公司后续公告，感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800022012.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301569"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678314152","title":"联亚药业：该在研产品目前处在FDA药监审评阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2678314152","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678314152?lang=zh_cn&edition=full","pubTime":"2026-10-27 11:33","pubTimestamp":1793071999,"startTime":"0","endTime":"0","summary":"证券之星消息，联亚药业(301569)10月27日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司结合雌激素软膏剂型HM-153目前处在Fda药监审评阶段吗？此首仿药预计明年1季度美国上市还是今年年底上市？谢谢。联亚药业回复：尊敬的投资者您好！该在研产品目前处在FDA药监审评阶段，研发进展存在不确定性，后续相关情况请关注公司公告。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700018757.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301569","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678158921","title":"股市必读：联亚药业（301569）登10月26日交易所龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2678158921","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678158921?lang=zh_cn&edition=full","pubTime":"2026-10-27 02:55","pubTimestamp":1793040954,"startTime":"0","endTime":"0","summary":"截至2026年10月26日收盘，联亚药业报收于18.89元，上涨2.55%，换手率38.37%，成交量44.83万手，成交额8.31亿元。当日关注点交易信息汇总：联亚药业主力资金净流入1042.61万元，占总成交额1.25%；  交易信息汇总：联亚药业因日换手率达30%登龙虎榜，系近5个交易日内第3次上榜。龙虎榜上榜沪深交易所2026年10月26日公布的交易公开信息显示，联亚药业因日换手率达到30%的前5只证券登上龙虎榜。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102700003969.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301569","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678013527","title":"股市必读：联亚药业（301569）登10月23日交易所龙虎榜","url":"https://stock-news.laohu8.com/highlight/detail?id=2678013527","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678013527?lang=zh_cn&edition=full","pubTime":"2026-10-26 01:16","pubTimestamp":1792948572,"startTime":"0","endTime":"0","summary":"截至2026年10月23日收盘，联亚药业报收于18.42元，上涨5.26%，换手率41.71%，成交量48.73万手，成交额8.68亿元。当日关注点交易信息汇总：联亚药业10月23日主力资金净流入3500.99万元，占总成交额4.03%；  交易信息汇总：联亚药业因日换手率达30%登上沪深交易所龙虎榜，系近5个交易日内第2次上榜。此次是近5个交易日内第2次上榜。结合雌激素缓释片180天市场独占期自该产品首次商业销售之日起算，具体日期以美国FDA公开信息为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102600000405.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301569","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677474399","title":"公司问答丨联亚药业：关于10亿片产能的爬坡节奏 目前未有量化时间表","url":"https://stock-news.laohu8.com/highlight/detail?id=2677474399","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677474399?lang=zh_cn&edition=full","pubTime":"2026-10-23 17:26","pubTimestamp":1792747593,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","301569"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677945252","title":"联亚药业：结合雌激素缓释片技术壁垒高","url":"https://stock-news.laohu8.com/highlight/detail?id=2677945252","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677945252?lang=zh_cn&edition=full","pubTime":"2026-10-23 15:06","pubTimestamp":1792739181,"startTime":"0","endTime":"0","summary":"证券之星消息，联亚药业(301569)10月23日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司结合雌激素缓释片除了原研药外，目前或今后一段时间是否会有其他厂家的高仿药竟争？该品种除美国外，公司是否已在其他国家（含国内）开展上市注册程序？谢谢。联亚药业回复：尊敬的投资者您好！结合雌激素缓释片技术壁垒高，截至目前，除原研外，暂无其他企业该仿制药获批，短期内暂无其他仿制药直接竞争；该品种现阶段优先深耕美国市场，其他市场尚在评估中。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300022681.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301569"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677199945","title":"联亚药业：硝苯地平缓释片（AB1,AB2）主要在美国获批销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2677199945","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677199945?lang=zh_cn&edition=full","pubTime":"2026-10-23 15:03","pubTimestamp":1792738989,"startTime":"0","endTime":"0","summary":"证券之星消息，联亚药业(301569)10月23日在投资者关系平台上答复投资者关心的问题。投资者提问：请问硝苯地平缓释片（AB1，AB2），除美国外，是否在其他国家（含中国）开展上市注册？有无上市时间表？谢谢。联亚药业回复：尊敬的投资者您好！截至目前，硝苯地平缓释片（AB1,AB2）主要在美国获批销售，公司将评估其他市场申报机会，目前暂无明确的上市时间表，感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300022655.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301569"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677110945","title":"联亚药业：盐酸美金刚缓释胶囊已获FDA及国家药监局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2677110945","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677110945?lang=zh_cn&edition=full","pubTime":"2026-10-23 15:03","pubTimestamp":1792738989,"startTime":"0","endTime":"0","summary":"证券之星消息，联亚药业(301569)10月23日在投资者关系平台上答复投资者关心的问题。投资者提问：公司产品适应证覆盖有阿尔茨海默症吗，目前研发进程如何？联亚药业回复：尊敬的投资者您好！公司用于治疗阿尔茨海默症的产品盐酸美金刚缓释胶囊已获美国FDA以及国家药品监督管理局批准上市，非在研产品。该产品目前在美国市场正常销售，暂未开展国内销售，感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300022656.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301569"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677891553","title":"联亚药业（301569）10月22日主力资金净卖出7095.64万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677891553","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677891553?lang=zh_cn&edition=full","pubTime":"2026-10-23 09:11","pubTimestamp":1792717882,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月22日收盘，联亚药业报收于17.5元，下跌12.76%，换手率41.03%，成交量47.94万手，成交额8.8亿元。近5日资金流向一览见下表：联亚药业融资融券信息显示，融资方面，当日融资买入5992.88万元，融资偿还5308.43万元，融资净买入684.45万元，连续3日净买入累计1557.48万元。联亚药业主营业务：复杂药物制剂的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300009295.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301569"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677996582","title":"联亚药业：公司现阶段尚未大规模应用AI工具于研发生产环节","url":"https://stock-news.laohu8.com/highlight/detail?id=2677996582","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677996582?lang=zh_cn&edition=full","pubTime":"2026-10-22 20:48","pubTimestamp":1792673312,"startTime":"0","endTime":"0","summary":"证券之星消息，联亚药业10月22日在投资者关系平台上答复投资者关心的问题。公司现阶段尚未大规模应用AI工具于研发生产环节。后续公司将持续跟踪AI技术在医药研发与生产的应用前景，结合自身研发生产的实际需求审慎选择落地场景。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102200039741.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301569","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677956052","title":"10月22日联亚药业（301569）龙虎榜数据：机构净买入237.06万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677956052","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677956052?lang=zh_cn&edition=full","pubTime":"2026-10-22 17:57","pubTimestamp":1792663079,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年10月22日公布的交易公开信息显示，联亚药业因日换手率达到30%的前5只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年10月22日收盘，联亚药业报收于17.5元，下跌12.76%，换手率41.03%，成交量47.94万手，成交额8.8亿元。从龙虎榜公布的当日买卖数据来看，机构合计净买入237.06万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102200031111.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301569","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677498181","title":"C联亚（301569）10月21日主力资金净卖出6726.58万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677498181","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677498181?lang=zh_cn&edition=full","pubTime":"2026-10-22 09:10","pubTimestamp":1792631459,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月21日收盘，C联亚报收于20.06元，下跌9.19%，换手率44.56%，成交量52.07万手，成交额10.97亿元。10月21日的资金流向数据方面，主力资金净流出6726.58万元，占总成交额6.13%，游资资金净流出6159.52万元，占总成交额5.61%，散户资金净流入1.29亿元，占总成交额11.74%。融资融券余额9159.56万元。C联亚主营业务：复杂药物制剂的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102200008020.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301569"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677662514","title":"联亚药业：公司有2项抗肿瘤相关在研项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2677662514","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677662514?lang=zh_cn&edition=full","pubTime":"2026-10-21 15:36","pubTimestamp":1792568167,"startTime":"0","endTime":"0","summary":"证券之星消息，C联亚(301569)10月21日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司有抗肿瘤药物研发能力吗？？C联亚回复：尊敬的投资者您好！截至目前，公司有2项抗肿瘤相关在研项目，尚处于早期研发阶段，存在不确定性，具体情况详见公司《招股说明书》，感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102100021665.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301569","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793836107527,"stockEarnings":[{"period":"1week","weight":0.1122},{"period":"1month","weight":2.0157},{"period":"ytd","weight":2.0157}],"compareEarnings":[{"period":"1week","weight":0.0013},{"period":"1month","weight":-0.0406},{"period":"3month","weight":-0.0549},{"period":"6month","weight":-0.1181},{"period":"1year","weight":-0.0692},{"period":"ytd","weight":-0.0712}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"南通联亚药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"95573人(较上一季度增加637053.33%)","perCapita":"1222股","listingDate":"2026-10-15","address":"江苏省南通市崇川区经济技术开发区综合保税区广兴路1号","registeredCapital":"89159万元","survey":"　　南通联亚药业股份有限公司主营业务是复杂药物制剂的研发、生产和销售。公司的主要产品及服务包括以不同类型的缓控释制剂以及低剂量药物制剂为代表的两大类高端仿制药。公司获FDA批准注册的口服制剂总ANDA数量排名国内第三，口服缓控释制剂获FDA批准数量排名国内第一，自主研发获得FDA认证的对照标准制剂（RS）数量排名国内第一，多个缓控释制剂在美国市场占有率排名第一。","listedPrice":7},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"联亚药业(301569)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供联亚药业(301569)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"联亚药业,301569,联亚药业股票,联亚药业股票老虎,联亚药业股票老虎国际,联亚药业行情,联亚药业股票行情,联亚药业股价,联亚药业股市,联亚药业股票价格,联亚药业股票交易,联亚药业股票购买,联亚药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"联亚药业(301569)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供联亚药业(301569)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}